Zyla Drug Patent Portfolio
Zyla owns 4 orange book drugs protected by 17 US patents Given below is the list of Zyla's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9044402 | Abuse-deterrent pharmaceutical compositions for controlled release | 01 Jul, 2033 | Active |
| US9549899 | Abuse deterrent pharmaceutical compositions for controlled release | 01 Jul, 2033 | Active |
| US8679544 | Formulation of diclofenac | 23 Apr, 2030 | Active |
| US8999387 | Formulation of diclofenac | 23 Apr, 2030 | Active |
| US9017721 | Formulation of diclofenac | 23 Apr, 2030 | Active |
| US9173854 | Formulation of diclofenac | 23 Apr, 2030 | Active |
| US9180095 | Formulation of diclofenac | 23 Apr, 2030 | Active |
| US9180096 | Formulation of diclofenac | 23 Apr, 2030 | Active |
| US9186328 | Formulation of diclofenac | 23 Apr, 2030 | Active |
| US7201920 | Methods and compositions for deterring abuse of opioid containing dosage forms | 16 Mar, 2025 | Active |
| US9492443 | Abuse deterrent compositions and methods of making same | 26 May, 2024 | Expired |
| US7510726 | Methods and compositions for deterring abuse of opioid containing dosage forms | 26 Nov, 2023 | Expired |
| US7981439 | Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof | 26 Nov, 2023 | Expired |
| US8409616 | Extended release opioid abuse deterrent compositions and methods of making same | 26 Nov, 2023 | Expired |
| US8637540 | Compositions for deterring abuse of opioid containing dosage forms | 26 Nov, 2023 | Expired |
| US6333044 | Therapeutic compositions for intranasal administration which include KETOROLAC® | 25 Dec, 2018 | Expired |
| US7476689 | Therapeutic compositions for intranasal administration which include KETOROLAC | 11 Oct, 2012 | Expired |
Latest Legal Activities on Zyla's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Zyla.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 08 Jul, 2024 | US9492443 |
|
Expire Patent
Critical
| 21 Aug, 2023 | US7981439 |
|
Expire Patent
Critical
| 10 Jul, 2023 | US9044402 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 17 May, 2023 | US9186328 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 May, 2023 | US9180096 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 10 May, 2023 | US9180095 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 03 May, 2023 | US9173854 |
|
Maintenance Fee Reminder Mailed
Critical
| 06 Mar, 2023 | US7981439 |
|
Maintenance Fee Reminder Mailed
Critical
| 23 Jan, 2023 | US9044402 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 28 Oct, 2022 | US9017721 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Oct, 2022 | US8999387 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 07 Jul, 2022 | US9017721 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 07 Jul, 2022 | US8999387 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 Mar, 2022 | US8637540 |
|
Email Notification
Critical
| 15 Mar, 2022 | US9492443 |
Zyla's Drug Patent Litigations
Zyla's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 13, 1997, against patent number US6333044. The petitioner , challenged the validity of this patent, with SANTUS et al as the respondent. Click below to track the latest information on how companies are challenging Zyla's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9017721 | December, 2015 |
Terminated-Denied
(01 Jul, 2016)
| iCeutica Pty Ltd. | Lupin Pharmaceuticals, Inc. |
| US8999387 | December, 2015 |
Terminated-Denied
(29 Jun, 2016)
| iCeutica Pty Ltd. | Lupin Pharmaceuticals, Inc. |
| US6333044 | June, 1997 |
Decision
(28 Aug, 2000)
| SANTUS et al | |
Zyla's Family Patents
Zyla Drug List
Given below is the complete list of Zyla's drugs and the patents protecting them.
1. Arymo Er
Arymo Er is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9044402 | Abuse-deterrent pharmaceutical compositions for controlled release |
01 Jul, 2033
(8 years from now)
| Active |
| US9549899 | Abuse deterrent pharmaceutical compositions for controlled release |
01 Jul, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Arymo Er's drug page
2. Oxaydo
Oxaydo is protected by 6 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7201920 | Methods and compositions for deterring abuse of opioid containing dosage forms |
16 Mar, 2025
(2 months from now)
| Active |
| US9492443 | Abuse deterrent compositions and methods of making same |
26 May, 2024
(6 months ago)
| Expired |
| US7510726 | Methods and compositions for deterring abuse of opioid containing dosage forms |
26 Nov, 2023
(1 year, 23 days ago)
| Expired |
| US7981439 | Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof |
26 Nov, 2023
(1 year, 23 days ago)
| Expired |
| US8409616 | Extended release opioid abuse deterrent compositions and methods of making same |
26 Nov, 2023
(1 year, 23 days ago)
| Expired |
| US8637540 | Compositions for deterring abuse of opioid containing dosage forms |
26 Nov, 2023
(1 year, 23 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxaydo's drug page
3. Sprix
Sprix is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6333044 | Therapeutic compositions for intranasal administration which include KETOROLAC® |
25 Dec, 2018
(5 years ago)
| Expired |
| US7476689 | Therapeutic compositions for intranasal administration which include KETOROLAC |
11 Oct, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sprix's drug page
4. Zorvolex
Zorvolex is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8679544 | Formulation of diclofenac |
23 Apr, 2030
(5 years from now)
| Active |
| US8999387 | Formulation of diclofenac |
23 Apr, 2030
(5 years from now)
| Active |
| US9017721 | Formulation of diclofenac |
23 Apr, 2030
(5 years from now)
| Active |
| US9173854 | Formulation of diclofenac |
23 Apr, 2030
(5 years from now)
| Active |
| US9180095 | Formulation of diclofenac |
23 Apr, 2030
(5 years from now)
| Active |
| US9180096 | Formulation of diclofenac |
23 Apr, 2030
(5 years from now)
| Active |
| US9186328 | Formulation of diclofenac |
23 Apr, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zorvolex's drug page